Celcuity's Drug Trial Results Show Significant Efficacy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Source: stocktwits
- Clinical Trial Results: Celcuity's experimental drug gedatolisib demonstrated a 50% reduction in the risk of disease progression or death in late-stage breast cancer patients, marking the first Phase 3 trial where this drug class clearly outperformed another, despite concerns over patient deaths.
- Survival Data: In patients with PIK3CA mutations, the median progression-free survival for the gedatolisib triplet and doublet therapies reached 11.1 months and 11.3 months respectively, significantly higher than the standard treatment's 5.6 months, indicating its potential to extend patient survival.
- Safety Analysis: While there were treatment-related deaths, the safety profile of gedatolisib remained consistent with earlier data, with serious side effects occurring in only 2.6% and 3.8% of patients in the triplet and doublet groups, respectively, compared to 7.1% in the standard treatment group.
- Market Reaction: Despite a 26% drop in stock price due to death reports, retail sentiment around CELC shifted from 'neutral' to 'extremely bullish', reflecting optimism towards the upcoming FDA decision, with CELC stock gaining approximately 687% over the past 12 months.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CELC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CELC
Wall Street analysts forecast CELC stock price to rise
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 88.280
Low
94.00
Averages
106.50
High
126.00
Current: 88.280
Low
94.00
Averages
106.50
High
126.00
About CELC
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor of phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), mechanistic target of rapamycin (mTOR) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. A Phase III clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (HR+/HER2-) advanced breast cancer (ABC) has completed enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (WT) tumors, and has completed enrollment of cohort 2, patients with PIK3CA mutant-type (MT) tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Celcuity Upsizes $500M Convertible Notes Offering
- Upsized Offering: Celcuity increased its convertible notes offering from $400 million to $500 million, indicating strong market demand for financing, which is expected to enhance the company's liquidity to support R&D efforts.
- Bond Details: The 0.250% convertible notes will mature in 2032, with initial purchasers granted a 30-day option to buy an additional $75 million in notes, further encouraging investor participation in the offering.
- Clear Use of Proceeds: The net proceeds are earmarked for the continued development and potential commercialization of its lead drug candidate, gedatolisib, as well as for working capital and general corporate purposes, reflecting the company's confidence in future growth.
- Market Reaction: Following the bond offering announcement, Celcuity's stock traded 1.9% lower in after-hours trading on Wednesday, indicating a cautious market sentiment regarding the company's short-term outlook, which may affect investor confidence.
See More
Celcuity Inc. Upsizes Public Offering of Convertible Notes
- Upsized Offering: Celcuity Inc. has increased its public offering of convertible senior notes from $400 million to $500 million, indicating a strong response to market demand and flexibility in its financing strategy.
- Clear Use of Proceeds: The estimated net proceeds of $484.3 million, or $557 million if underwriters fully exercise their option, will be used to repay loans, for general corporate purposes, and for acquisitions, enhancing the company's financial stability and competitive position.
- Attractive Bond Terms: The convertible notes carry an interest rate of 0.250% per year, payable semi-annually, with a conversion price of $124.53 per share, which may attract investor interest and potentially boost the company's stock performance.
- Negative Market Reaction: Following the announcement, Celcuity Inc.'s stock price fell by 2.70%, further declining to $87.20 in after-hours trading, reflecting market concerns over the offering and potentially impacting investor confidence.
See More
Celcuity Inc. Prices Upsized $500 Million Convertible Notes Offering
- Upsized Offering: Celcuity Inc. announced an increase in its convertible notes offering from $400 million to $500 million, reflecting strong market demand, with the offering expected to close on June 8, 2026, enhancing the company's liquidity.
- Interest and Conversion Terms: The convertible notes carry an annual interest rate of 0.250%, with an initial conversion rate of 8.0302 shares per $1,000 principal amount, translating to a conversion price of approximately $124.53, representing a 40% premium over the current stock price, providing investors with potential capital appreciation.
- Clear Use of Proceeds: The company estimates net proceeds of approximately $484.3 million from the offering, primarily to repay all outstanding obligations under its loan agreement with Oxford Finance, with remaining funds allocated for working capital and clinical trial expenditures, ensuring ongoing investment in R&D and market launch activities.
- Strong Underwriting Team: The offering is managed by prominent financial institutions including Jefferies and J.P. Morgan, which bolsters market confidence in Celcuity and lays the groundwork for potential future business expansions and technology acquisitions.
See More
Celcuity Plans $400 Million Convertible Senior Notes Offering
- Financing Plan: Celcuity announced its intention to offer $400 million of convertible senior notes due in 2032, aimed at providing funding support for the company's operations and R&D.
- Over-Allotment Option: The company will grant underwriters a 30-day option to purchase up to an additional $60 million of notes to meet market demand, enhancing the offering's flexibility.
- Use of Proceeds: The net proceeds from this offering will be used to repay all outstanding obligations under its loan agreement with Oxford Finance, as well as for clinical trials, commercialization activities, and other general corporate purposes.
- Market Condition Impact: Celcuity noted that the completion of the offering remains subject to market and other conditions, with no assurances regarding the timing, size, or final terms of the offering.
See More
Celcuity Proposes $400 Million Convertible Notes Offering
- Offering Size: Celcuity is proposing a public offering of $400 million in convertible senior notes, with an additional $60 million option for underwriters to cover over-allotments, indicating a strong market demand expectation from the company.
- Use of Proceeds: The net proceeds from this offering will be utilized to fully repay all outstanding obligations under its loan agreement with Oxford Finance, while the remainder will support clinical trials, commercialization, and R&D, enhancing the company's financial flexibility and competitive positioning.
- Bond Terms: The convertible notes will be general, unsecured senior obligations of the company, with interest payable semi-annually and a maturity date of August 1, 2032, allowing for flexible capital structure options as the company can choose cash, common stock, or a combination upon conversion.
- Market Conditions: The closing of the offering is subject to market and other conditions, and while uncertainties exist, Celcuity's strategic financing plan reflects its ongoing development potential in the biotechnology sector and confidence in future growth opportunities.
See More
Celcuity's Drug Trial Results Show Significant Efficacy
- Clinical Trial Results: Celcuity's experimental drug gedatolisib demonstrated a 50% reduction in the risk of disease progression or death in late-stage breast cancer patients, marking the first Phase 3 trial where this drug class clearly outperformed another, despite concerns over patient deaths.
- Survival Data: In patients with PIK3CA mutations, the median progression-free survival for the gedatolisib triplet and doublet therapies reached 11.1 months and 11.3 months respectively, significantly higher than the standard treatment's 5.6 months, indicating its potential to extend patient survival.
- Safety Analysis: While there were treatment-related deaths, the safety profile of gedatolisib remained consistent with earlier data, with serious side effects occurring in only 2.6% and 3.8% of patients in the triplet and doublet groups, respectively, compared to 7.1% in the standard treatment group.
- Market Reaction: Despite a 26% drop in stock price due to death reports, retail sentiment around CELC shifted from 'neutral' to 'extremely bullish', reflecting optimism towards the upcoming FDA decision, with CELC stock gaining approximately 687% over the past 12 months.
See More
Celcuity Upsizes $500M Convertible Notes Offering
- Upsized Offering: Celcuity increased its convertible notes offering from $400 million to $500 million, indicating strong market demand for financing, which is expected to enhance the company's liquidity to support R&D efforts.
- Bond Details: The 0.250% convertible notes will mature in 2032, with initial purchasers granted a 30-day option to buy an additional $75 million in notes, further encouraging investor participation in the offering.
- Clear Use of Proceeds: The net proceeds are earmarked for the continued development and potential commercialization of its lead drug candidate, gedatolisib, as well as for working capital and general corporate purposes, reflecting the company's confidence in future growth.
- Market Reaction: Following the bond offering announcement, Celcuity's stock traded 1.9% lower in after-hours trading on Wednesday, indicating a cautious market sentiment regarding the company's short-term outlook, which may affect investor confidence.
See More
Celcuity Inc. Upsizes Public Offering of Convertible Notes
- Upsized Offering: Celcuity Inc. has increased its public offering of convertible senior notes from $400 million to $500 million, indicating a strong response to market demand and flexibility in its financing strategy.
- Clear Use of Proceeds: The estimated net proceeds of $484.3 million, or $557 million if underwriters fully exercise their option, will be used to repay loans, for general corporate purposes, and for acquisitions, enhancing the company's financial stability and competitive position.
- Attractive Bond Terms: The convertible notes carry an interest rate of 0.250% per year, payable semi-annually, with a conversion price of $124.53 per share, which may attract investor interest and potentially boost the company's stock performance.
- Negative Market Reaction: Following the announcement, Celcuity Inc.'s stock price fell by 2.70%, further declining to $87.20 in after-hours trading, reflecting market concerns over the offering and potentially impacting investor confidence.
See More
Celcuity Inc. Prices Upsized $500 Million Convertible Notes Offering
- Upsized Offering: Celcuity Inc. announced an increase in its convertible notes offering from $400 million to $500 million, reflecting strong market demand, with the offering expected to close on June 8, 2026, enhancing the company's liquidity.
- Interest and Conversion Terms: The convertible notes carry an annual interest rate of 0.250%, with an initial conversion rate of 8.0302 shares per $1,000 principal amount, translating to a conversion price of approximately $124.53, representing a 40% premium over the current stock price, providing investors with potential capital appreciation.
- Clear Use of Proceeds: The company estimates net proceeds of approximately $484.3 million from the offering, primarily to repay all outstanding obligations under its loan agreement with Oxford Finance, with remaining funds allocated for working capital and clinical trial expenditures, ensuring ongoing investment in R&D and market launch activities.
- Strong Underwriting Team: The offering is managed by prominent financial institutions including Jefferies and J.P. Morgan, which bolsters market confidence in Celcuity and lays the groundwork for potential future business expansions and technology acquisitions.
See More
Celcuity Plans $400 Million Convertible Senior Notes Offering
- Financing Plan: Celcuity announced its intention to offer $400 million of convertible senior notes due in 2032, aimed at providing funding support for the company's operations and R&D.
- Over-Allotment Option: The company will grant underwriters a 30-day option to purchase up to an additional $60 million of notes to meet market demand, enhancing the offering's flexibility.
- Use of Proceeds: The net proceeds from this offering will be used to repay all outstanding obligations under its loan agreement with Oxford Finance, as well as for clinical trials, commercialization activities, and other general corporate purposes.
- Market Condition Impact: Celcuity noted that the completion of the offering remains subject to market and other conditions, with no assurances regarding the timing, size, or final terms of the offering.
See More
Celcuity Proposes $400 Million Convertible Notes Offering
- Offering Size: Celcuity is proposing a public offering of $400 million in convertible senior notes, with an additional $60 million option for underwriters to cover over-allotments, indicating a strong market demand expectation from the company.
- Use of Proceeds: The net proceeds from this offering will be utilized to fully repay all outstanding obligations under its loan agreement with Oxford Finance, while the remainder will support clinical trials, commercialization, and R&D, enhancing the company's financial flexibility and competitive positioning.
- Bond Terms: The convertible notes will be general, unsecured senior obligations of the company, with interest payable semi-annually and a maturity date of August 1, 2032, allowing for flexible capital structure options as the company can choose cash, common stock, or a combination upon conversion.
- Market Conditions: The closing of the offering is subject to market and other conditions, and while uncertainties exist, Celcuity's strategic financing plan reflects its ongoing development potential in the biotechnology sector and confidence in future growth opportunities.
See More
Celcuity's Drug Trial Results Show Significant Efficacy
- Clinical Trial Results: Celcuity's experimental drug gedatolisib demonstrated a 50% reduction in the risk of disease progression or death in late-stage breast cancer patients, marking the first Phase 3 trial where this drug class clearly outperformed another, despite concerns over patient deaths.
- Survival Data: In patients with PIK3CA mutations, the median progression-free survival for the gedatolisib triplet and doublet therapies reached 11.1 months and 11.3 months respectively, significantly higher than the standard treatment's 5.6 months, indicating its potential to extend patient survival.
- Safety Analysis: While there were treatment-related deaths, the safety profile of gedatolisib remained consistent with earlier data, with serious side effects occurring in only 2.6% and 3.8% of patients in the triplet and doublet groups, respectively, compared to 7.1% in the standard treatment group.
- Market Reaction: Despite a 26% drop in stock price due to death reports, retail sentiment around CELC shifted from 'neutral' to 'extremely bullish', reflecting optimism towards the upcoming FDA decision, with CELC stock gaining approximately 687% over the past 12 months.
See More
